Epoetin trials: Randomised controlled trials don't always mimic observational data

Nephrology Dialysis Transplantation

Volumn 22, Issue 3, 2007, Pages 684-686

  Roger, Simon D ^a   Levin, Adeera ^b  

^a GOSFORD HOSPITAL   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anaemia; CHOIR; Clinical trials; CREATE; Erythropoietin

Indexed keywords

CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; IRON; LIPID; PHOSPHATE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART DILATATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY DYSFUNCTION; MINERAL METABOLISM; MORTALITY; NOTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UREMIA;

ANEMIA; EPOETIN ALFA; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; OBSERVATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33847657893     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl740     Document Type: Note

References (23)

1. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354
2. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
3. Levin A, Djurdjev O, Barrett B et al. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 2001; 38: 1398-1407
4. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38 [4 Suppl 1]: S26-S29
5. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000; 15 [Suppl 3]: 23-28
6. McMahon LP, Mason K, Skinner SL et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-1430
7. Madore F, Lowrie EG, Brugnara C et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8: 1921-1929
8. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
9. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1997; 47: 186-192
10. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
11. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084-1090
12. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156
13. Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811
14. Strippoli GF, Craig JC. Hypothesis versus association: The optimal hemoglobin target debate. Am J Kid Dis 2005; 46: 970-973
15. Macdougall IC, Temple M, Kwan JTC. Is early treatment of anaemia with epoetin alfa beneficial to predialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomised, comparative group trial. Nephrol Dial Transplant
16. Historical review of predialysis chronic renal function patients in order to assess the possibility of predicting anaemia by simple laboratory parameters. Janssen-Cilag. Data on file, 1997
17. McMahon LP, Roger SD, Levin A. for the SLIMHEART investigators. The development, prevention and possible reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 13: 1640-1647
18. Rossert J, Levin A, Roger SD et al. Effect of early correction of anemia on the progression of CKD. Am J Kid Dis 2006; 47: 738-750
19. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 335: 2071-2084
20. Singh AK, Szczech L, Tang LK et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006; 355: 2085-2099
21. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153
22. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
23. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003; 84: S207-S210